In a series of parallel and collaborative preclinical studies, Dr . Miller and colleagues effectively blocked ocular neovascularization with a VEGF-neutralizing antibody ( bevacizumab ), a VEGF-neutralizing antibody fragment ( ranibizumab ), and a VEGF-neutralizing aptamer EYE001 ( later known as pegaptanib ).
22.
Recently, intravitreal injections of anti-VEGF agents, namely bevacizumab, a humanized monoclonal antibody targeted against pro-angiogenic, circulatory VEGF, and ranibizumab, a FDA-approved monoclonal antibody fragment that targets all VEGF-A isoforms, have shown improved visual outcome and reduced leakage in macular edema form diabetes and retinal venous occlusions.
23.
This includes innovative therapeutic and diagnostic products; novel drug delivery systems; protein / peptide therapeutics; monoclonal antibodies and antibody fragments; cytokines and cytokine receptors; recombinant DNA and gene regulation technology; gene therapy; nucleic acid therapeutics and diagnostics; stem cell therapies; drug target validation; glycolated and pegylated therapeutics; and pioneering technologies in drug design and development ..
24.
A "'single-domain antibody "'( "'sdAb "', called "'Nanobody "'by Ablynx, the developer ) is an antibody fragment consisting of a single monomeric light chains, and even smaller than Fab fragments ( ~ 50 kDa, one light chain and half a heavy chain ) and single-chain variable fragments ( ~ 25 kDa, two variable domains, one from a light and one from a heavy chain ).
25.
The " Boss patent " was owned by Celltech and covered methods of making recombinant antibodies and antibody fragments, together with vectors and host cells useful in these processes . that covered altered and native immunoglobulins prepared in recombinant cell culture, as well as the " New Cabilly " patent that covers artificial synthesis of antibody molecules . that covered high affinity human antibodies from transgenic mice.
